A Fully Automated Synthesis for the Preparation of 68Ga-labelled Peptides
Overview
Authors
Affiliations
Background: Generator-produced Ga has attracted increasing interest for radiolabelling peptides used in PET applications. So far, the synthesis of Ga-peptide radiopharmaceuticals is mainly based on semi-automated systems. Here we describe a fully automated approach for the synthesis of Ga-labelled peptides.
Method: A commercially available Ga generator was eluted with 0.1 mol . l HCl. Reaction parameters such as buffer conditions, pH range, reaction temperature and time, volume of reaction solution and generator fraction were optimized for labelling DOTA-Tyr-octreotide (DOTATOC). Reaction yields, pH, radiochemical purity, sterility, endotoxins, breakthrough of Ge and final Ge content were determined. A fully automated radiopharmaceutical synthesis device based on a modular concept for remote-controlled processing was developed and evaluated for a number of DOTA-derivatized peptides.
Results: DOTATOC could be labelled in almost quantitative yields by heating 10-50 nmol peptide at pH 3.5-4.0 for 5 min at 95 degrees C in 1.5 ml. Purification using a reversed-phase cartridge was required to avoid any potential Ge breakthrough: final activities of Ge were below 100 Bq . ml. Automated synthesis resulted in overall decay-corrected reaction yields of about 60% within 10 min. Even after 1 year using a 1110 MBq generator more than 130 MBq Ga-DOTATOC could be obtained. Moreover, it was demonstrated that a variety of DOTA-derivatized peptides can be labelled using identical reaction conditions with high yields.
Conclusion: The system described allows the fully automated, efficient and rapid preparation of Ga-DOTA-derivatized peptides. It has been used successfully and reliably for routine preparations in clinical studies.
Koatale P, Welling M, Mdanda S, Mdlophane A, Takyi-Williams J, Durandt C Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338315 PMC: 11434960. DOI: 10.3390/ph17091150.
Khorshidi A Heliyon. 2024; 10(10):e31499.
PMID: 38813197 PMC: 11133935. DOI: 10.1016/j.heliyon.2024.e31499.
Martin S, Wendlinger L, Litvinenko A, Faizova R, Schottelius M EJNMMI Radiopharm Chem. 2024; 9(1):23.
PMID: 38512591 PMC: 10957824. DOI: 10.1186/s41181-024-00254-2.
Iglseder S, Iglseder A, Beliveau V, Heugenhauser J, Gizewski E, Kerschbaumer J J Neurooncol. 2023; 164(3):711-720.
PMID: 37707754 PMC: 10589159. DOI: 10.1007/s11060-023-04414-3.
Good practices for Ga radiopharmaceutical production.
Nelson B, Andersson J, Wuest F, Spreckelmeyer S EJNMMI Radiopharm Chem. 2022; 7(1):27.
PMID: 36271969 PMC: 9588110. DOI: 10.1186/s41181-022-00180-1.